Home » Valeant Revives Growth Plan With $2.6 Billion Medicis Deal
Valeant Revives Growth Plan With $2.6 Billion Medicis Deal
Valeant Pharmaceuticals’ $2.6 billion agreement to buy skin-care company Medicis Pharmaceutical recharges an acquisition plan that stumbled with last year’s failed bid for Cephalon.
San Francisco Chronicle
San Francisco Chronicle
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May